Cargando…
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393334/ https://www.ncbi.nlm.nih.gov/pubmed/32737423 http://dx.doi.org/10.1038/s41440-020-0515-0 |
_version_ | 1783565022915461120 |
---|---|
author | Shibata, Shigeru Arima, Hisatomi Asayama, Kei Hoshide, Satoshi Ichihara, Atsuhiro Ishimitsu, Toshihiko Kario, Kazuomi Kishi, Takuya Mogi, Masaki Nishiyama, Akira Ohishi, Mitsuru Ohkubo, Takayoshi Tamura, Kouichi Tanaka, Masami Yamamoto, Eiichiro Yamamoto, Koichi Itoh, Hiroshi |
author_facet | Shibata, Shigeru Arima, Hisatomi Asayama, Kei Hoshide, Satoshi Ichihara, Atsuhiro Ishimitsu, Toshihiko Kario, Kazuomi Kishi, Takuya Mogi, Masaki Nishiyama, Akira Ohishi, Mitsuru Ohkubo, Takayoshi Tamura, Kouichi Tanaka, Masami Yamamoto, Eiichiro Yamamoto, Koichi Itoh, Hiroshi |
author_sort | Shibata, Shigeru |
collection | PubMed |
description | Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry receptor and that hypertension as well as cardiovascular disorders frequently coexist with COVID-19 have generated considerable discussion on the management of patients with hypertension. In addition, the COVID-19 pandemic necessitates the development of and adaptation to a “New Normal” lifestyle, which will have a profound impact not only on communicable diseases but also on noncommunicable diseases, including hypertension. Summarizing what is known and what requires further investigation in this field may help to address the challenges we face. In the present review, we critically evaluate the existing evidence for the epidemiological association between COVID-19 and hypertension. We also summarize the current knowledge regarding the pathophysiology of SARS-CoV-2 infection with an emphasis on ACE2, the cardiovascular system, and the kidney. Finally, we review evidence on the use of antihypertensive medication, namely, ACE inhibitors and angiotensin receptor blockers, in patients with COVID-19. |
format | Online Article Text |
id | pubmed-7393334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-73933342020-07-31 Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 Shibata, Shigeru Arima, Hisatomi Asayama, Kei Hoshide, Satoshi Ichihara, Atsuhiro Ishimitsu, Toshihiko Kario, Kazuomi Kishi, Takuya Mogi, Masaki Nishiyama, Akira Ohishi, Mitsuru Ohkubo, Takayoshi Tamura, Kouichi Tanaka, Masami Yamamoto, Eiichiro Yamamoto, Koichi Itoh, Hiroshi Hypertens Res Review Article Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry receptor and that hypertension as well as cardiovascular disorders frequently coexist with COVID-19 have generated considerable discussion on the management of patients with hypertension. In addition, the COVID-19 pandemic necessitates the development of and adaptation to a “New Normal” lifestyle, which will have a profound impact not only on communicable diseases but also on noncommunicable diseases, including hypertension. Summarizing what is known and what requires further investigation in this field may help to address the challenges we face. In the present review, we critically evaluate the existing evidence for the epidemiological association between COVID-19 and hypertension. We also summarize the current knowledge regarding the pathophysiology of SARS-CoV-2 infection with an emphasis on ACE2, the cardiovascular system, and the kidney. Finally, we review evidence on the use of antihypertensive medication, namely, ACE inhibitors and angiotensin receptor blockers, in patients with COVID-19. Springer Singapore 2020-07-31 2020 /pmc/articles/PMC7393334/ /pubmed/32737423 http://dx.doi.org/10.1038/s41440-020-0515-0 Text en © The Japanese Society of Hypertension 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Shibata, Shigeru Arima, Hisatomi Asayama, Kei Hoshide, Satoshi Ichihara, Atsuhiro Ishimitsu, Toshihiko Kario, Kazuomi Kishi, Takuya Mogi, Masaki Nishiyama, Akira Ohishi, Mitsuru Ohkubo, Takayoshi Tamura, Kouichi Tanaka, Masami Yamamoto, Eiichiro Yamamoto, Koichi Itoh, Hiroshi Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 |
title | Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 |
title_full | Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 |
title_fullStr | Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 |
title_full_unstemmed | Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 |
title_short | Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 |
title_sort | hypertension and related diseases in the era of covid-19: a report from the japanese society of hypertension task force on covid-19 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393334/ https://www.ncbi.nlm.nih.gov/pubmed/32737423 http://dx.doi.org/10.1038/s41440-020-0515-0 |
work_keys_str_mv | AT shibatashigeru hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT arimahisatomi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT asayamakei hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT hoshidesatoshi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT ichiharaatsuhiro hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT ishimitsutoshihiko hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT kariokazuomi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT kishitakuya hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT mogimasaki hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT nishiyamaakira hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT ohishimitsuru hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT ohkubotakayoshi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT tamurakouichi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT tanakamasami hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT yamamotoeiichiro hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT yamamotokoichi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 AT itohhiroshi hypertensionandrelateddiseasesintheeraofcovid19areportfromthejapanesesocietyofhypertensiontaskforceoncovid19 |